Journal Article

Coronary stenting and abciximab in primary angioplasty for ST-segment-elevation myocardial infarction

G. De Luca, H. Suryapranata, R. Grimaldi and M. Chiariello

in QJM: An International Journal of Medicine

Published on behalf of Association of Physicians of Great Britain and Ireland

Volume 98, issue 9, pages 633-641
Published in print September 2005 | ISSN: 1460-2725
Published online July 2005 | e-ISSN: 1460-2393 | DOI:
Coronary stenting and abciximab in primary angioplasty for ST-segment-elevation myocardial infarction

Show Summary Details


Advances in anti-platelet therapy and improvement of stent deployment techniques have improved the safety and efficacy of stenting in the setting of ST-segment-elevation myocardial infarction (STEMI). However, in randomized trials, routine coronary stenting does not reduce mortality and re-infarction, compared to balloon angioplasty. Further, the benefits in target vessel revascularization seem to be reduced when applied to unselected patients with STEMI. Direct stenting represents an attractive strategy with potential benefits in terms of myocardial perfusion. Future large randomized trials are needed to evaluate whether this strategy has a significant impact on outcome, and to provide a cost-benefit analysis of the unrestricted use of drug-eluting stents in this high-risk subset of patients. The additional use of abciximab reduces mortality in primary angioplasty. Since the feasibility of long-distance transportation has been shown in several randomized trials, early pharmacological pre-treatment may confer further advantages by early recanalization and shorter ischaemic time, particularly in high-risk patients. Further randomized trials are needed to clarify the potential benefits from early abciximab administration and the potential role of small molecules in primary angioplasty for STEMI.

Journal Article.  4688 words.  Illustrated.

Subjects: Medicine and Health

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.